Announced details
Pediatric atopic dermatitis in children aged 2 to under 12, atopic dermatitis in adults and children aged 12 and over, and plaque psoriasis in adults
Superiority to the vehicle cream was demonstrated on the primary endpoint after once-daily treatment for 8 weeks. Safety was evaluated after treatment for up to 60 weeks, confirming favorable tolerability.
鳥居薬品株式会社 is a SHIONOGI group company. SHIONOGI & CO., LTD. is the marketing authorization holder and 鳥居薬品株式会社 is the distributor, with the two companies conducting domestic co-promotion. JAPAN TOBACCO INC. and 鳥居薬品株式会社 have entered into a domestic joint development and marketing agreement. JAPAN TOBACCO INC. transferred its pharmaceutical business to SHIONOGI & CO., LTD.
鳥居薬品株式会社 is headquartered in Chuo-ku, Tokyo, and its Representative Director and President is Kondo Shinya (近藤紳雅). The company has contractual relationships with JAPAN TOBACCO INC. and Dermavant Sciences GmbH. Other details are not disclosed.
SHIONOGI & CO., LTD.: Kita-ku, Osaka; 鳥居薬品株式会社: Chuo-ku, Tokyo
The impact on consolidated results for the fiscal year ending March 2027 will be minor.
The company does not address Contract Value / Offering price.
jRCT (Clinical Research and Other Studies Submission and Disclosure System), jRCT2031230139; JAPAN TOBACCO INC. press release (24 June 2024)
| Item | Details |
|---|---|
| Names of Products / Services Covered | VTAMA® Cream 0.5%, VTAMA® Cream 1% |
| Counterparty | 鳥居薬品株式会社, JAPAN TOBACCO INC., Dermavant Sciences GmbH, Organon & Co. |
| Counterparty overview | 鳥居薬品株式会社 is headquartered in Chuo-ku, Tokyo, and its Representative Director and President is Kondo Shinya (近藤紳雅). The company has contractual relationships with JAPAN TOBACCO INC. and Dermavant Sciences GmbH. Other details are not disclosed. |
| Relationship with the Company | 鳥居薬品株式会社 is a SHIONOGI group company. SHIONOGI & CO., LTD. is the marketing authorization holder and 鳥居薬品株式会社 is the distributor, with the two companies conducting domestic co-promotion. JAPAN TOBACCO INC. and 鳥居薬品株式会社 have entered into a domestic joint development and marketing agreement. JAPAN TOBACCO INC. transferred its pharmaceutical business to SHIONOGI & CO., LTD. |
| Contract Date | 2020 (domestic exclusive development and commercialization rights agreement between JAPAN TOBACCO INC. and Dermavant Sciences GmbH) |
| Applicable area | Pediatric atopic dermatitis in children aged 2 to under 12, atopic dermatitis in adults and children aged 12 and over, and plaque psoriasis in adults |
| Location | SHIONOGI & CO., LTD.: Kita-ku, Osaka; 鳥居薬品株式会社: Chuo-ku, Tokyo |
| Quantitative Effects | Superiority to the vehicle cream was demonstrated on the primary endpoint after once-daily treatment for 8 weeks. Safety was evaluated after treatment for up to 60 weeks, confirming favorable tolerability. |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 will be minor. |
| Source | jRCT (Clinical Research and Other Studies Submission and Disclosure System), jRCT2031230139; JAPAN TOBACCO INC. press release (24 June 2024) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The domestic Phase 3 clinical trial demonstrated superiority to the vehicle cream on the primary endpoint after 8 weeks of treatment, as well as favorable tolerability after treatment for up to 60 weeks.